Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

New Data Position Lazertinib As Strong Contender In 1L NSCLC

Potential Tagrisso Challenger?

Dec 07 2022

• By Jung Won Shin

lung cancer — New Indication Filing for Lazertinib Expected In Korea in Q1 '23 • Source: Shutterstock

Related Companies

Yuhan Corporation

Janssen Pharmaceutical Cos.

AstraZeneca PLC

Additional Topics

South Korea Asia Pacific Clinical Trials Research & Development Cancer BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.